Javascript not enabled

Industry News

December 2014

Corin Group acquires Australian orthopaedic technology leader Optimized Ortho

 

 

Corin Group acquires technology to help improve component positioning in total hip replacement

Corin Group PLC, a leading global manufacturer and supplier of orthopaedic devices, has acquired Optimized Ortho, an Australian orthopaedics technology company that specialises in providing surgeons with unique state of the art technologies for optimising orthopaedic implant component positioning and procedural innovation.

 

The acquisition provides Corin with an IP-protected technology that is the first of its kind within the orthopaedic field. The combination of the Optimized Positioning System (OPS™) technology, alongside the company’s strong hip portfolio and rapidly expanding global distribution network, provide a strong foundation for future growth of the company.

 

Every patient has a unique pelvic motion which influences how a total hip replacement will function in day-to-day activities. The OPS™ technology, for the first time, gives the surgeon the ability to identify, customise and deliver an exact patient-specific component orientation designed to optimise biomechanics and functional joint performance.

 

A simple physical assessment and imaging protocol generates data unique to the patient which is then analysed using patented simulation software to determine their individual kinematic and pelvic motion profile. Implants are then accurately placed to optimise function using a unique and highly accurate laser-guided alignment system.

 

This solution is a significant step forward in helping to improve the performance of total hip replacement for an ageing and more active patient population as conventional acetabular cup placement does not take into account the individual’s functional movement and relies on guidance for cup positioning defined some 36 years ago (Lewinnek JBJS 1978). By acquiring OPS™ technology, Corin is able to offer surgeons and patients a unique, customised, patient-specific solution for hip surgery that will help to provide optimal implant positioning and improved functional outcome.

Commenting on the announcement, Stefano Alfonsi, Chief Executive Officer of Corin, said: “We are delighted to have the ability to integrate this technology into our compelling product portfolio. We recognise that further improvements in hip replacement require developments around procedural innovation as well as implant design. Our vision for the future will be to lead in the area of personalised healthcare, with a specific focus on individual patient-specific dynamics. The integration of the Optimized Ortho technology into Corin continues to strengthen our position as a fast moving innovation company that focuses on the needs of patients and surgeons.”

Brad Miles, Chief Technology Officer at Optimized Ortho, added: “We are very excited to be entering into this agreement with one of the most dynamic and proactive global orthopaedic implant organisations. Over the past year we have worked closely with Corin in Australia to combine OPS™ technology with their leading hip brands and this deal marks a major milestone in creating a game changing solution for hip patients worldwide.”

 

Following the success of Trinity OPS™ in Australia over the past year, Corin is now poised to roll the system out to its other global markets. 


July 2014

Comprehensive revision guides for FRCS Trauma and Orthopaedic exam published

A new series of books, designed to help candidates sitting their FRCS Trauma and Orthopaedic examination, have been published. The revision books have been written to address a gap in the market and are based on feedback from candidates on the revision courses run by South Warwickshire Foundation Trust (SWFT).

The author, Faiz Hashmi, an orthopaedic surgeon who works for SWFT, said: “When I was preparing for my own FRCS Trauma and Orthopaedic examinations, there were no revision books available that encompassed the whole syllabus. I initially started writing up a few questions to help myself, and then realised that all candidates could benefit from this support material.”

The first book is designed to test the candidate’s knowledge of Section one theory, through extended matching items, whilst Book 2 concentrates on clinical examination. A further two books will follow in the series, covering Section Two and the Viva.

The books, along with other training materials and courses which include Sections one and two of the FRCS Trauma and Orthopaedics and EBOT examination, as well as the syllabus of the American and Canadian Board are available on www.orthopaedicstraining.com


18 June 2014

 

Medacta Highlights Knee, Hip, and Spine Surgery Best Practices at 7th International Symposium

Reflects long-standing commitment to surgical training, education, and patient outcomes

Coincides with Medacta’s 15th anniversary and latest product milestones

 

April 11, 2014 - M.O.R.E. International Symposium 2014

Medacta International, a privately held, family-owned global leader in the design of innovative joint replacement and spine surgery products, hosted the occurrence of its 7th Medacta Orthopaedic Research and Education (M.O.R.E.) International Symposium, near the company’s worldwide headquarters in Lugano, Switzerland.

During the two-day event, approximately 1,000 delegates attended lectures by a faculty of internationally recognised experts on topics including surgical best practices, emerging clinical data, and planned enhancements for Medacta joint and spine surgery products.

The Symposium coincided with significant milestones as Medacta celebrated its 15th anniversary as a Company, founded with a vision of creating a better patient experience for people needing joint replacement, its 10th anniversary for AMIS (Anterior Minimally Invasive Approach for hip replacement) and its 5th anniversary for MyKnee (Patient matched technology for knee replacement).

The M.O.R.E. International Symposium underlined Medacta’s commitment to further advance surgical education and training that has shown to improve patient safety and reduce the cost of orthopaedic care and recovery.

More than 60 orthopaedic surgery experts from around the world presented. Professor Michael Freeman, MD (Royal University Hospital/University College London, UK) participated as honorary Chairman, with the keynote address delivered by Daniel Berry, MD (Mayo Clinic, Rochester, MN). Frédéric Laude, MD (Clinique Paris V, Paris, FR) and Joel Matta, MD (Hip and Pelvis Institute, Santa Monica, CA) served as Chairmen of the Hip Programme. Craig Loucks, MD and Robert Greenhow, MD (Peak Orthopedics, Denver, CO) chaired the Knee Programme.

 “Medacta is unique in its focus on surgeon education and training, and its approach to collaborating with the surgical community to improve the art, science, and outcomes of orthopaedic procedures,” said Dr. Frédéric Laude, a pioneer in the anterior approach to hip replacement and a co-chair of the Symposium’s Hip Programme. “Having taught many anterior hip replacement courses myself, I’ve seen firsthand the impact that education, mentorship, and a robust training curriculum can have on surgical efficiency and the patient experience.”

Medacta products have seen rapid adoption by surgeons, patients, and healthcare organisations alike since the company’s incorporation. To date, the company’s MyKnee Patient Matched Technology has been used in over 15,000 procedures worldwide.

Last year Medacta documented the 110,000th surgical procedure performed via the AMIS technique for Hip Arthroplasty. Medacta has also entered into the spine market with precision-engineered spine implants and instruments, and is applying its proven 3D-reconstruction and rapid 3D-printing technologies to assist spine surgeons on the most complex deformity cases.

For the first time, this year’s M.O.R.E. International Symposium included a distinct summit on spine care options, strategies, and treatment decisions.

The International Spine Summit ran concurrently alongside the hip and knee tracks, and included its own distinguished international faculty of more than 30 orthopaedic spine and neurosurgery experts. It also featured an honorary lecture by Max Aebi, MD, (Hirslanden Hospital Group, Switzerland) on the history and evolution of spinal instrumentation techniques.

The abstracts from the 7th MORE Symposium are collected in the addendum to the June issue of BJJ while recordings of the entire scientific session will be available in streaming at: www.7more.medacta.com

ABOUT MEDACTA INTERNATIONAL. Medacta International is a world leading manufacturer of orthopaedic implants, neurosurgical systems and instrumentation. Medacta’s revolutionary approach and responsible innovation have resulted in standard of care breakthroughs in hip replacement with the AMIS system and total knee replacement with MyKnee patient matched technology. Over the last 10 years, Medacta has grown dramatically by taking a holistic approach and placing value on all aspects of the care experience from design to training to sustainability. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in 30 countries.


June  2014

We would like to take this opportunity to thank all our customers and associates for visiting our exhibition stand at this year’s EFORT congress. The exhibition was a great success for MatOrtho® and gave us the opportunity to showcase many of our products, including the Medial Rotation Knee™ which celebrates 20 years of clinical use in 2014. We hope you enjoyed the show and we look forward to seeing you again in the near future.

 

 


23 March 2012

Next generation vitamin E highly cross-linked polyethylene gains FDA clearance

Corin adds the next generation vitamin E polyethylene to its high performance bearing options for the Trinity™ advanced acetabular system following FDA 510(k) clearance.

In February, Corin received 510(k) clearance from the FDA for ECiMa™ highly cross-linked polyethylene liners to be used in combination with the large diameter Cobalt Chrome and BIOLOX® delta ceramic heads (up to 40mm) for its Trinity™ acetabular system.  

This announcement marks another significant step forward for Corin's hip portfolio in the US following a number of 510(k) clearances in 2011, which enables the company to offer a range of high performance bearing solutions within a versatile Continuum of Hip Care to surgeons across the country. Corin's Continuum of Hip Care offers the surgeon the ability to select the right implant for a broad spectrum of patient indications with a range of choices that focus on bone conservation, hip stability, fixation and wear. Today's patient population is placing greater demands on their hip replacements and the ability to address individual surgeon and patient requirements is a fundamental part of a modern day hip portfolio.

ECiMa™ represents the world’s first highly cross-linked vitamin E polyethylene which is mechanically annealed, preserving the mechanical properties such as strength whilst achieving extremely low wear1,2. Studies show that ECiMa™ reduces wear in a 40mm bearing by 95% compared to a standard 32mm polyethylene bearing. When compared to a first generation highly cross-linked polyethylene, used by many major orthopaedic companies, ECiMa™ reduces wear by 83%1. The ultimate tensile strength of ECiMa™ is also comparable to that of standard polyethylene and is a 45% improvement on the first generation highly cross-linked polyethylenes2. These excellent wear characteristics and mechanical properties allow the use of optimised bearings to help restore function to the hip and help provide the potential for better long-term results for patients.  

The ultimate benefit of ECiMa™ is generated through the active stabilisation provided by the blended vitamin E which has been shown through various studies to provide ongoing protection against oxidation of the polyethylene whilst in the hip joint. The free radical stabilisation effect of vitamin E provides a natural barrier to potential long-term oxidation which can occur in vivo. Test results show no evidence of oxidation following intensive ageing and cyclic loading in vitro where previous HXLPE liners have failed3.

Katherine Granger, Corin's Global Head of Hip Marketing, commented "ECiMa™ is an excellent addition to the Trinity™ acetabular system offering surgeons and patients the most advanced bearing technology within an innovative system.  ECiMa™ is the next generation vitamin E-enriched technology and the most advanced polyethylene on the market, providing a high performance alternative to hard bearings. As such, future plans include the roll-out of ECiMa™ to some of our knee products, and others, across Corin’s wider portfolio.”

References:

1.    Traynor A, Simpson DJ, Collins SN. Vitamin E HXLPE for low wear and oxidation resistance of hip bearings. International Society of Biomechanics. Brussels. July 2011.
2.    Data held on file Corin Group PLC.
3.    Data held on file Corin Group PLC.

For further information about Corin Group PLC, please visit www.coringroup.com.

 



 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

17 February 2012

Mathys posts stable growth

In spite of a difficult economic climate, Mathys improved its currency-adjusted sales by 7 % in 2011 while the number of employees remained stable.

The orthopaedics company Mathys, based in Bettlach, can look back on a successful but challenging year. The family-owned company posted consolidated sales of CHF 111.2 million in 2011. "Currency-adjusted real growth was 7 % because, as an export-centric company, we are still affected by the currency crisis," explains Dr. Arne-C. Faisst, CEO of the Mathys Group. The company lost around CHF 7.8 million to currency effects. While the weak euro could still be countered relatively well by productivity increases in 2010, the weakness of the dollar made things worse in 2011 and created a difficult situation for Swiss manufacturers that benefited their American competitors. "The US manufacturers pass on the currency gains directly to the markets in the form of price cuts. This made our situation more difficult," explains Arne Faisst. The company nevertheless posted double-digit growth in some countries. While sales improved by 30 % in the home market Switzerland, the family-owned company also generated double-digit growth in France, the Netherlands, Austria and Australia.

Number of employees remained stable

The number of employees remained stable in spite of the economic challenges. Mathys currently employs 465 persons, 274 in Switzerland and 191 at its eleven subsidiaries worldwide.

Japanese subsidiary becomes operational

The Japanese subsidiary established in 2009 will go operational in 2012. "Product registration in Japan has kept us very busy the past two years. As planned we can now start selling our products in Japan this year – the first Japanese patient received a Mathys hip prosthesis back in January," says a delighted Arne Faisst. With Japan and China, Mathys is now represented in two important Asian markets.

Outlook

The outlook for this year is positive. As the company’s ongoing investments in innovative products are now bearing fruit and excellent clinical results on various products are leading to a full product pipeline, the Executive Board expects the current momentum to continue. Mathys expects solid growth for 2012, too.

General Information about Mathys Ltd Bettlach

The Swiss Orthopaedic company was founded in 1946 and looks back on 50 years of experience in the field of medical technique. Since 1 November 2003 Mathys concentrates solely on the development, production and supply of joint replacement products, produced predominantly in Switzerland and also in Germany. The company currently focuses on implants for hip, knee and shoulder and in addition synthetic bone replacement material.

The company has 11 Subsidiaries in Germany, France, Belgium, the United Kingdom, Holland, Austria, Australia, New Zealand, P. R. China, Japan and Switzerland and is owned by the families Mathys and Marzo. Hugo Mathys holds the position of Chairman of the Board of Directors; Dr. Arne Faisst is CEO and Chairman of the Executive Board.

 

Question should please be addressed to:

Regula Haag, Head Corporate- and Market Communication

Mathys Ltd Bettlach, Güterstrasse 5, P. O. Box, 2544 Bettlach, Switzerland

Telephone direct:        +41 (0)32 644 14 97

Mobile-Nr.:                 +41 (0)79 593 89 35

Fax direct:                   +41 (0)32 644 14 60

E-mail:                         regula.haag@mathysmedical.com

Switchboard:             +41 (0)32 644 1 644